# MTD-DRF STUDIES-TO 4

> **NIH NIH N01** · IIT RESEARCH INSTITUTE · 2024 · $224,716

## Abstract

BPN programs have launched a series of collaborative drug discovery and development projects focused on supporting preclinical optimization and development of safe, effective, and non-addictive
small molecule and biologic therapeutics to treat pain and other neurological disorders. These projects are developing therapeutic candidates through an iterative process of lead optimization,
in vitro and in vivo testing. A component of this process is the conduct of in vivo maximum tolerated dose (MTD) and dose-range finding (DRF) toxicity assessment of compounds. This task
order is non-rodent (MTD) and DRF studies of a compound generated by BPN Program.

## Key facts

- **NIH application ID:** 11211352
- **Project number:** 75N95021D00026-0-759502400003-1
- **Recipient organization:** IIT RESEARCH INSTITUTE
- **Principal Investigator:** MICHAEL O'RYAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $224,716
- **Award type:** —
- **Project period:** 2024-03-15 → 2024-09-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11211352

## Citation

> US National Institutes of Health, RePORTER application 11211352, MTD-DRF STUDIES-TO 4 (75N95021D00026-0-759502400003-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11211352. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*